Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111393 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL8648964 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL27467945 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL18480 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL18189054 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL9290791 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL92711 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL8166655 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL780212 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C | |
| SCHEMBL122858 | 1.00 | HTR6 (0.43) | HTR6CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853667-A | Chiral pyridoxal catalyst and preparation method and application thereof | 上海师范大学 | 2022-08-05 | — | — | CN | claimed |
| CN-106831862-B | Chiral bridged axial chiral monophosphine ligand and preparation method thereof | 中山大学 | 2021-01-15 | — | — | CN | claimed |
| CN-111094265-A | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2020-05-01 | — | — | CN | claimed |
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | claimed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | claimed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | claimed |
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | claimed |
| US-8809335-B2 | Pyrazolopyrimidine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | claimed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | claimed |
| CN-102131807-B | Pyrazolopyridine kinase inhibitors | VERTEX PHARMA | 2013-11-20 | — | — | CN | claimed |
| WO-2010011768-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011762-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011772-A2 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2121613-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | claimed |
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | claimed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | claimed |
| US-20060035920-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005118583-A1 | 2, 5-DIHYDRO-PYRAZOLO`4, 3-C!QUINOLIN-4-ONES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HTR6 3265/4885CHRM5 4665/4885ADRA2C 3050/4885 |
| US-20060035920-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | HTR6 3259/4885CHRM5 4829/4885ADRA2C 3929/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HTR6 3265/4885CHRM5 4665/4885ADRA2C 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.